FRUITS-ECO-BLOCKCHAIN
4.11.2022 15:01:43 CET | Business Wire | Press release
Fruits Eco-Blockchain Project (hereinafter, Fruits), a blockchain project striving towards financial inclusion and a sustainable ecosystem, has released a message of support from boxing legend and eight-division boxing world champion Manny Pacquiao and a roadmap for future activities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221101006428/en/
Manny Pacquiao supports Fruits (Graphic: Business Wire)
Mr. Pacquiao has expressed his support upon collaboration with Fruits.
We will be working with Mr. Pacquiao to create a world where one’s consumption leads to another’s enhancement by using the sustainable ecosystem as envisioned by Fruits.
Please click the following URL to watch the video.
(Video URL)
https://youtu.be/l_Y6xuJjLWk
Roadmap
- Started deliberations with Mr. Pacquiao for launching a charity project in the Philippines. Discussions will continue until November 2022
- Commence the sale of subscription-based NFT for supporting charities by the end of 2022
- Launch of Fruits’ first blockchain game that promotes contributions to charity at the beginning of 2023
- Renewal of Fruits Station and organization of a periodic charity event using crowdfunding scheduled to launch in the end of Q1 2023
- Launch projects and organize charity events in collaboration with international sports legends in boxing, soccer, and other fields from March 2023 onwards
Details will be posted on the official homepage in due course.
[Support for the Fruits Station Donation Project]
Fruits is involved in charity initiatives through Fruits Station (https://fruits-station.com) to help the famine-stricken and impoverished citizens of the world.
We are undergoing a large-scale renewal and a crowdfunding-based charity platform is scheduled to launch in the end of Q1 2023.
Through this project, we want to build a sustainable ecosystem in collaboration with global influential individuals including Mr. Pacquiao and other legendary athletes.
Please see the roadmap of our charity activities to be conducted with the support of Mr. Pacquiao.
We are building a sustainable ecosystem to ensure children and families struggling with various issues become self-sufficient and have access to financial services.
What is Fruits
-
Fruits Official Website
https://fruitsblockchain.com/ -
Fruits Official Telegram (English)
https://t.me/fruits_official -
Fruits Official Linktree
https://linktr.ee/fruitsecoblockchain -
Fruits Official Medium (English)
https://medium.com/@fruitsblockchain -
FRUITS Station
https://fruits-station.com
“Fruits Wallet” Application Download
-
App Store
https://apps.apple.com/jp/app/fruits-wallet/id1585148044 -
Google Play
https://play.google.com/store/apps/details?id=com.fruits.wallet&hl=ja&gl=US
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221101006428/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom